Paigevs
Ibex Medical Analytics
Ibex Medical Analytics: If you want a pathology AI vendor whose primary business remains pathology rather than genomics
Paige
Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus
As of 1 September 2026, Paige's pricing is not published; the vendor quotes on request. Paige Prostate Detect was the first AI pathology product authorised by the FDA, and it is authorised only as an adjunct on prostate core needle biopsies viewed through Paige FullFocus. Softwr lists it under Healthcare. Paige is made by Paige AI, Inc., a Tempus company, available on Web, Self-hosted.
Overview
What Paige does
Paige builds AI applications for computational pathology, spun out of Memorial Sloan Kettering. Its clinical products cover prostate, breast, lymph node and other tissue types, with the Paige Prostate suite comprising Detect, Grade and Quantify and perineural invasion. FullFocus is the accompanying whole slide viewer. Alongside the clinical line, Paige sells foundation models and OmniScreen products into biopharma for prescreening and biomarker characterisation, and has introduced Alba as a multimodal pathology copilot. The regulatory position is the reason Paige matters and also the reason buyers overestimate it. In September 2021 Paige Prostate received the first ever FDA De Novo marketing authorisation for an AI pathology algorithm. The authorised indication is narrow and specific: an adjunct to review of digitised prostate core needle biopsy slides scanned on a compatible scanner and viewed through the FullFocus viewer, identifying areas of interest for pathologist review. It does not diagnose, it does not grade under that authorisation, and it does not extend to other tissue types. In Europe the Paige Prostate suite obtained IVDR certification in 2025, which is a broader position covering grading and quantification. The pivotal study reported that pathologists using the software detected cancer on individual slides more often, with reported reductions in false negative and false positive readings. Buyers are hospital and reference pathology laboratories that have already digitised, plus pharmaceutical companies buying the research side. The trade off is prerequisite cost. Paige is useless without whole slide scanning, image storage and a digital pathology workflow already in place, and that infrastructure typically costs an order of magnitude more than the algorithm. Tempus acquired Paige in 2025, so contracting, support and roadmap now sit inside a larger precision medicine business with its own commercial priorities around genomic data.
What people use it for
- A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable
- A pathology department already digitised that wants a documented safety net against missed small foci of cancer
- A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reporting
- A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variability
The honest half
Where it falls short
Concrete and checkable, so you can decide whether any of them matter to you. This is the half of a review a vendor will not write about Paige.
- The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
- The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
- Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
- Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
- Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.
Cross-shopped
What people choose instead of Paige
Each pairing was judged by two reviewers asking whether a buyer would genuinely weigh the two against each other. The ones that failed were deleted rather than published.
- PaigevsSectra
Sectra: If the immediate need is the digital pathology workflow and archive rather than the algorithm
- PaigevsBenchling
Benchling: If the requirement is research data management rather than clinical diagnostic support
Pricing
What Paige costs
Taken from the vendor's own pricing page. Prices move, so check before you buy.
Paige clinical applications
On request
- Priced per case or per slide analysed under annual agreement
- Prostate, breast and other applications licensed separately
- Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication
- Life sciences foundation model access contracted separately
Capabilities
Features
Paige Prostate Detect
FDA De Novo authorised adjunct for identifying suspicious areas on prostate core needle biopsies
Paige Prostate Grade and Quantify
Gleason grading and tumour quantification, available under IVDR in Europe
Perineural invasion detection
Flags perineural invasion on prostate specimens
Breast and lymph node applications
Cancer detection and metastasis identification on breast tissue
FullFocus viewer
FDA cleared whole slide viewer required for the authorised prostate indication
Foundation models
Pathology foundation models licensed for research and product development
OmniScreen
Prescreening and biomarker characterisation products aimed at biopharma
Paige Alba
Multimodal pathology copilot spanning slide, report and clinical context
Answered, with sources
Questions people ask
Each answer names the page it came from, so you can check it rather than take our word for it.
What exactly is FDA authorised?
Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.
Is the European position broader?
Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.
What did the pivotal study measure?
Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.
Who owns Paige now?
Tempus AI acquired Paige in 2025. Products remain branded Paige.
Keep looking
Where to go from Paige
- Paige alternativesEvery product people weigh against it
- Paige pricingPlans, floors and what the tiers exclude
- Paige badgesWhich rules it meets, and the figure behind each
- All Healthcare softwareThe full category
- Best Healthcare softwareThe shortlist, and how it was cut
Best Healthcare software for
Compare Paige with
- Ibex Medical Analytics
- Sectra
- PathAI
- Techcyte
- Lunit
- Gleamer
- Annalise.ai
- Therapixel
- Aidoc
- Koa Health
- Ambra Health
- DHIS2
- Kareo
- NextGen Enterprise EHR
- Omada Health
- OpenClinica
- PathAI
- Kareo Clinical
Other Healthcare software
Cancer detection AI for breast, prostate and gastric pathology deployed in routine clinical service, not just pilots
Pricing on request12 researched notesEnterprise imaging and PACS from a Swedish vendor that also sells the pathology and cardiology modules on one platform
Pricing on request12 researched notesDigital pathology image management with an FDA cleared platform for primary diagnosis
Pricing on request11 researched notesAI digital pathology across clinical, veterinary and environmental laboratory disciplines
Pricing on request11 researched notesFDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography
Pricing on request11 researched notesCE marked and FDA cleared imaging AI suite for bone trauma and chest, now owned by RadNet
Pricing on request12 researched notesMulti-finding chest X-ray and head CT triage AI with FDA clearance on named findings, not on the whole model
Pricing on request12 researched notesFrench mammography AI with FDA clearances for 2D and tomosynthesis breast screening
Pricing on request11 researched notesFDA cleared radiology AI for triage and notification of time critical findings
Pricing on request11 researched notesEmployer and health plan digital mental health, acquired by PsychPlus in June 2026
Pricing on request12 researched notesCloud medical image exchange and vendor neutral archive, now part of Intelerad
Pricing on request12 researched notesOpen source health information platform run from the University of Oslo and used by national ministries
Open source12 researched notesEnterprise-grade EHR and RCM for large healthcare organizations
Pricing on request6 researched notesClinical trial EDC with a genuinely open source community edition alongside a quoted commercial platform
Pricing on request9 researched notesDigital pathology image management with an FDA cleared platform for primary diagnosis
Pricing on request11 researched notesSpecialized EHR and practice management for independent and small practices
From $89/mo12 researched notes
Softwr does not host reviews and shows no star rating for Paige, because a rating we did not collect is not ours to publish. What is here is the pricing and platform detail from the vendor’s own pages, limitations we could state concretely, and alternatives a reviewer confirmed people weigh against it. Tell us if any of it is wrong.
More on Paige
Paige alternatives
What people switch to, and what they give up
Paige pricing
Every tier, and where the cost actually lands
Compare Paige
Put it head to head with anything we hold
Paige badge
Its rating, and an embed for your own site
Best Healthcare software alternatives
Clinical laboratory middleware and informatics from a diagnostics instrument manufacturer
quote
Open source hospital information system and EMR for low-resource hospitals, built on OpenMRS
Open source, no licence fee
Period and cycle tracking app owned by German company Biowink, positioned around science based tracking and a published stance against sharing data with law enforcement
Free with a Plus subscription
Period and cycle tracking app that settled with the US FTC in 2021 over sharing health data with third parties despite promising not to
Free with a Premium subscriptionOpen source health information platform run from the University of Oslo and used by national ministries
Open source, no licence feeMulti-finding chest X-ray and head CT triage AI with FDA clearance on named findings, not on the whole model
quote